Body Composition and Body Mass Index Show Comparable Associations with Adalimumab Exposure and…

Cross-sectionalJournal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics· Jul 2026

Body Composition and Body Mass Index Show Comparable Associations with Adalimumab Exposure and Immunogenicity in Noninfectious Uveitis.

Francesco Pichi, Rauda Shehab, Piergiorgio Neri

Read paper

UveitisCross-sectionalQ2IF 2.1

Higher body mass index is associated with lower adalimumab drug levels in uveitis patients.

Body Composition and Body Mass Index Show Comparable Associations with Adalimumab Exposure and Immunogenicity in Noninfectious Uveitis.

Francesco Pichi … Piergiorgio Neri

Journal of ocular pharmacology and therapeutics · Jul 2026 · Q2 in Ophthalmology

Purpose

To evaluate whether bioimpedance-derived body composition parameters are associated with adalimumab exposure and immunogenicity in noninfectious uveitis (noninfectious uveitis) and whether they provide information complementary to body mass index (BMI).

Methods

Forty-five patients with noninfectious uveitis receiving adalimumab monotherapy (40 mg every 2 weeks) for at least 12 months were enrolled in this single-center cross-sectional study.

Results

r = -0.51

higher BMI tends to go with lower adalimumab drug levels in blood

More results

In separate multivariable models adjusted for age and sex, each adiposity measure was independently associated with trough concentrations (adjusted R 2 0.18-0.25).

ROC analysis showed comparable discrimination of low drug exposure for BMI (area under the curve [AUC] 0.69) and body composition metrics (AUC 0.70-0.74; DeLong P > 0.5).

More results

BMI showed the strongest correlation with anti-adalimumab antibodies levels ( r = 0.58, P < 0.0001).

“

Conclusion · 1 of 3

Bioimpedance-derived adiposity measures and BMI showed similar associations with adalimumab exposure in noninfectious uveitis.

Conclusion · 2 of 3

Body composition may offer complementary biological context for interpreting pharmacokinetic variability and immunogenicity.

Conclusion · 3 of 3

Future studies are warranted to determine whether body composition data improve therapeutic drug monitoring in uveitis.

Body Composition and Body Mass Index Show Comparable Associations with Adalimumab Exposure and Immunogenicity in Noninfectious Uveitis.

Body Composition and Body Mass Index Show Comparable Associations with Adalimumab Exposure and Immunogenicity in Noninfectious Uveitis.

Related papers